Hester Biosciences closes trading window from October 1 for Q2FY27

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Trading window closed from October 1, 2026
  • Closure applies to Q2FY27 and H1FY27 results
  • Window reopens 48 hours after results are public
  • Compliance with SEBI insider trading regulations
powered bylight_fuzz_icon
51855658

*this image is generated using AI for illustrative purposes only.

Hester Biosciences has closed its trading window for dealing in equity shares starting October 1, 2026. This measure is implemented ahead of the announcement of financial results for the quarter and six months ended September 30, 2026.

Regulatory compliance and timeline

The company stated that the closure is pursuant to the SEBI (Prohibition of Insider Trading) Regulations and its internal code of conduct. This code regulates and monitors trading by directors, promoters, designated employees, specified connected persons, and material subsidiaries, including their immediate relatives.

The trading window will remain closed until 48 hours after the financial results become generally available as public information. This standard protocol ensures that insiders do not trade while possessing unpublished price-sensitive information.

Key dates and details

Detail Information
Company Hester Biosciences
Closure Start Date October 1, 2026
Reporting Period Q2FY27 and H1FY27
Period End Date September 30, 2026
Reopening Condition 48 hours post-publication

The communication was signed by Vinod Mali, Company Secretary and Compliance Officer, on September 25, 2026. The notice was filed with both BSE Limited and the National Stock Exchange of India Limited.

Historical Stock Returns for Hester Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.10%-2.08%-7.00%+60.48%+12.28%-11.95%

How might Hester Biosciences' Q2FY27 revenue performance compare to the previous quarter given recent trends in the veterinary vaccine market?

What impact could the upcoming financial results have on Hester Biosciences' stock volatility once the trading window reopens?

Are there any pending regulatory approvals or new product launches expected to influence the company's earnings outlook for FY27?

Hester Biosciences shareholders approve promoter reclassification

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Shareholders approved reclassifying two promoters as public shareholders
  • Resolution passed with 99.99% assent via remote e-voting
  • Mr. Ravin Gandhi and Ms. Bela Gandhi affected by the change
  • Promoter group polled 77.42% of shares with full support
powered bylight_fuzz_icon
50044434

*this image is generated using AI for illustrative purposes only.

Hester Biosciences shareholders approved the reclassification of two promoter group members as public shareholders via a postal ballot. The ordinary resolution passed with 99.99% assent on September 4, 2026.

The company sought approval under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders voted through remote e-voting between August 5 and September 3, 2026. Central Depository Services (India) Limited facilitated the voting process.

Voting Results

A total of 89 shareholders cast valid votes representing 3,981,963 shares. Two votes comprising 40,227 shares were declared invalid. The promoters and promoter group held no interest in the resolution.

Category Shares Held Votes Polled Votes in Favour Votes Against
Promoter Group 4,570,944 3,538,635 3,538,635 -
Public Institutional 31,483 11,414 11,253 161
Public Others 3,904,438 431,914 431,648 266
Total 8,506,865 3,981,963 3,981,536 427

Reclassification Details

The resolution affects Mr. Ravin Gandhi and Ms. Bela Gandhi. Both individuals hold less than 10% of the paid-up equity share capital and do not exercise control over the company. They are not represented on the Board of Directors or as key managerial personnel.

Mr. Ravin Gandhi holds 403,320 shares (4.74% of paid-up capital). Ms. Bela Gandhi holds 400,635 shares (4.71% of paid-up capital). The outgoing promoters confirmed they are not willful defaulters or fugitive economic offenders.

What the Numbers Show

The promoter group demonstrated high engagement, polling 77.42% of their outstanding shares with unanimous support for the reclassification. In contrast, public institutional holders showed lower participation at 36.25%, while public retail participation stood at 11.06%.

Historical Stock Returns for Hester Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.10%-2.08%-7.00%+60.48%+12.28%-11.95%

How will the reclassification of Ravin and Bela Gandhi as public shareholders impact Hester Biosciences' promoter holding percentage and future dilution norms under SEBI regulations?

Given the low retail participation rate of 11.06%, what strategies might the company employ to improve minority shareholder engagement in future corporate actions?

Could this reclassification signal a broader shift in ownership structure that might pave the way for potential divestment or liquidity events for the Gandhi family?

More News on Hester Biosciences

1 Year Returns:+12.28%